Edition:
United Kingdom

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Global Market

8.47USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$8.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
46,103
52-wk High
$11.47
52-wk Low
$4.30

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  RDHL.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -- -- --
ROI: -- 0.21 14.27
ROE: -- 1.17 15.99

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

30 Jul 2018

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV, July 30 Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

30 Jul 2018

BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share

* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial

* REDHILL BIOPHARMA ANNOUNCES LAST PATIENT ASSESSED FOR PRIMARY ENDPOINT IN RHB-104 PHASE III STUDY FOR CROHN’S DISEASE

07 May 2018

BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia

* REDHILL BIOPHARMA ANNOUNCES ENROLLMENT OF 300TH PATIENT IN CONFIRMATORY PHASE III STUDY WITH TALICIA® FOR H. PYLORI INFECTION

04 May 2018

Earnings vs. Estimates

No consensus analysis data available.